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AT CDTT Stenting
Femoral vein 60% 100% 2/26
External iliac vein 60% 100% 6/26
Common iliac vein 50% 80% 8/26
IVC 25% 60% -
Follow up: Mean e 1 year (8monthse 19months); Recurrence of
DVT e 2/26; PTS e 0/26 and Pulmonary Embolism e 0/26.
Conclusion: Interventional approach for acute DVT is successful,
promising and feasible. Rapid removal and lysis results in pre-
serving venous valve functions and reducing the incidence of PTS.
Stem cell augmentation for cardiovascular risk in
Rheumatoid Arthritis: STAR study
A. Syngle, N. Garg, P. Krishan, I. Verma
Healing Touch City Clinic Chandigarh, Punjabi University, Patiala, India
Background: Bone marrow derived stem cells, endothelial pro-
genitor cells (EPCs), protect against atherosclerotic vascular
damage. However, EPCs are depleted in RA and contribute to the
enhanced cardiovascular (CV) risk. Therapeutic potential of aug-
menting EPCs to treat the heightened CV risk of RA has not yet
been exploited. We aimed to investigate the effect of rosuvastatin
on EPCs population, endothelial dysfunction, nitrite, adhesion
molecules and on markers of inflammation in RA.
Methods: 50 RA patients, randomized to receive 24 weeks of
treatment with rosuvastatin (10mg/day, n¼25) or placebo (n¼25)
as an adjunct to existing stable antirheumatic drugs. EPCs (CD34+/
CD133+) were quantified by Flow Cytometry. Flow mediated
dilatation (FMD) was assessed by AngiodefenderTM (Everest
Genomic Ann Arbor, United States). Inflammatory measures
included DAS28, CRP, ESR, Pro-inflammatory cytokines (TNF-a, IL-
6 and IL-1), levels of serum nitrite, lipids and adhesion molecules
(ICAM-1 and VCAM-1) was done at baseline and after treatment.
Results: At baseline, inflammatory measures, pro-inflammatory
cytokines, adhesion molecules and nitrite levels were elevated
and EPCs and endothelial function were impaired among both
groups. At 24 wks: DAS28, ESR, CRP, TNF-a, IL-6, nitrite and ICAM-
1 improved significantly in rosuvastatin group. EPCs increased
significantly after treatment with rosuvastatin as compared with
placebo. FMD improved significantly in the rosuvastatin group.
Rosuvastatin exerted positive effect on lipids. Significant inverse
correlation observed between EPCs and CRP, TNF-a, ICAM-1and
FMD after rosuvastatin treatment.
Conclusion: First study to show that rosuvastatin augments EPCs
population in RA mediated by lowering the cytokine levels, which
downregulates adhesion molecule, CRP and nitric oxide produc-
tion. This defines a novel mechanism of rosuvastatin treatment in
RA: the augmentation of EPCs with improvement in inflammatory
disease activity and endothelial dysfunction.
New oral anticoagulants in atrial fibrillation
L. Sumithra, S.S. Iyengar, V. Subash Chandra, G. Sridhara,
Roshan D'silva
Manipal Hospital, India
Background: Atrial fibrillation (AF) is a common arrhythmia, and
is an important cause of stroke. Risk of stroke and bleeding need
to be assessed before initiating anticoagulant treatment. New oral
anticoagulants (NOACs) are available now as an alternative to
vitamin K antagonists (VKA).
Objective: Our objective was to study the incidence of valvar AF
versus nonvalvar AF, the scores for risk of stroke and bleeding and
the use of NOACs in a tertiary case hospital.
Methods: Cases of atrial fibrillation hospitalized or seen in out
patient over a period of two years were studied. CHA2DS2VASc
and HASBLED scores were applied to all cases of nonvalvar AF.
Creatinine clearance was calculated by Cockroft formula.
Results: There were 60 patients of AF, 30 being male. Mean age
was 66.6 years overall, 62.6 years for male and 70.6 for female
patients. 43 (71.6 %) patients had nonvalvar AF and 17 (28 .4 %) had
valvar AF. OF 17 cases of valvular AF, 04 had prosthetic valve and
all were on VKA.
For the 43 patients of nonvalvar AF, the mean CHA2DS2VASc
score was 2.8 and the mean HASBLED score was 1.5. Fifteen pa-
tients received dabigatran. Of these 15 patents, one shifted from
VKA to dabigatran as she found frequent INR monitoring incon-
venient. 35 opted for VKA for economic reasons and 5 declined to
have any anticoagulation. In one patient, oral anticoagulation was
not started since he had subdural hematoma. In four patients, oral
anticoagulation was not indicated as the CHA2DS2VASc score was
0. Amongst 15 patients who received dabigatran, 11 were on 110
mg twice a day dose because of age, renal dysfunction and body
weight, 4 were on 150 mg twice a day. All these patients tolerated
dabigatran well.
Conclusion: There were more nonvalvar AF cases than valvar AF
and female patients were older. CHA2DS2VASc and HASBLED
scores are easy to apply and help in decision making on initiation
of oral anticoagulants in nonvalvar AF patients. Dabigatran is an
attractive alternative to VKA to prevent stroke in nonvalvar AF.
Cost, compliance, comorbidites and coadministration of other
drugs may be constraints for the use of NOACs.
To study Troponin T levels and its significance in
relation to mortality and morbidity in acute
ischemic stroke
A. Lalchandani, Anand Kumar Singh, P. Paliwal, M. Godara,
M. Naveen, T. Midha, A. Garg, A.N. Singh, P. Singh
PG Institute of Medicine, GSVM Medical College, Kanpur, India
Background: Troponin T levels have been shown to have a very
good correlation with cardiac stroke or myocardial infarction. In
this study Troponin T levels were evaluated in patients of acute
ischemic stroke.
It follows that Troponin T levels must have a correlation with
morbidity and mortality in these patients (pt.).
Methods: Pt of acute ischemic stroke confirmed by CT scan or MRI
within 72 hr of stroke onset, admitted in medicine ward of L.L.R
and associated hospital in G.S.V.M medical college Kanpur and
measurement of cTn T between 12-72 hr of stroke onset. There
were 45 patients in study who were admitted over a period of
January 2010 to September 2011.
Results: 17.8% of patients in study show rise in troponin T
(>0.01mcgm/dl) out of which 37.5% pt had poor outcome while
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21.6% pt in normal troponin T group had poor outcome (P value
0.0146). After 30 days follow up 50% pt died in elevared troponin
group while only 13.5% pt died in normal troponin group (P value
0.0389).
Conclusion: In patients of acute ischemic stroke with raised
troponin T level there was increased morbidity (P value 0.0146)
and mortality (P value 0.0146) which was found to be statistically
significant.
Rates of hemorrhage during warfarin therapy for
atrial fibrillation
S.A. Punekar, S. Gavade, A.R. Taksande, H.C. Shah, A.U. Mahajan,
P.J. Nathani, Y.Y. Lokhandwala
LTMG Hospital, Mumbai, India
Background: Although warfarin has been extensively studied in
clinical trials, little is known about rates of hemorrhage attribut-
able to its use in routine clinical practice. Our objective was to
examine incident hemorrhagic events in a municipal hospital
based cohort of patients with atrial fibrillation who were started
treatment with warfarin.
Methods: We conducted a municipal hospital based cohort study
involving patients (age  50 yr) with atrial fibrillation who started
taking warfarin between Jan 2013, and March 2014. We defined a
major hemorrhage as any visit to hospital for hemorrage. We
determined crude rates of hemorrhage duringwarfarin treatment,
overall and stratified by CHADS 2 score (congestive heart failure,
hypertension, age  75 yr, diabetes mellitus and prior stroke,
transient ischemic attack or thromboembolism).
Results: We included 469 patients with atrial fibrillation who
started treatment with warfarin during the study period. Overall,
the rate of hemorrhage was 3.5% (95% confidence interval [CI]
3.8%e3.9%) per person-year. The risk of major hemorrhage was
highest during the first 30 days of treatment. During this period,
rates of hemorrhage were 11.6% (95% CI 11.1%e12.5%) per person-
year in all patients and 15.6% (95% CI 14.3%e19.4%) per person-
year among patients with a CHADS 2 scores of 4 or greater. Over
the 13months follow-up, 38 patients (8.1%) visited the hospital for
hemorrhage; of these patients, 2 (5%) died in hospital.
Conclusions: In this municipal hospital based cohort of older pa-
tients with atrial fibrillation, we found that rates of hemorrhage
are highest within the first 30 days of warfarin therapy. These
rates are considerably higher than the rates of 1%e3% reported in
randomized controlled trials of warfarin therapy. Our study pro-
vides timely estimates of warfarin-related adverse events that
may be useful to clinicians, patients and policy-makers as new
options for treatment become available.
Experience of pulmonary embolism at J.J.hospital
Nitin Bote, Sandesh Prabhu, Sanjay Shivapuje, N.O. Bansal
Grant Medical College & Sir J J Group of Hospitals, Mumbai, India
Background: It is said pulmonary embolism is “a great imitator”. It
can present with different characteristics which can vary from
patient to patient in young vs elderly patients. Pulmonary embo-
lism (PE) is a blockage of the main pulmonary artery or one of its
branches by a substance that has travelled from elsewhere in the
body through the bloodstream. PE most commonly results from
deep vein thrombosis.
Symptoms of pulmonary embolism include dyspnea, tachy-
cardia, tachypnea, chest pain, palpiations, cyanosis, hypotension,
and sudden death. Diagnosis is based on these clinical findings
and imaging studies, usually CT pulmonary angiography. Treat-
ment is typically with anticoagulation. Severe cases may require
thrombolysis or may require catheter based intervention via
pulmonary thrombectomy.
Objective: The purpose of this study is to assess frequency, risk
factors, presenting symptoms, treatment, complications and In-
hospital outcomes of pulmonary embolism in young patients
compared with those of elderly patients.
Methods: We studied 18 patients of pulmonary embolism in < 40
years age group and 20 patients age more than 40 years admitted
in our hospital from August 2012 to July 2014.Patients with a
diagnosis of pulmonary embolism admitted to between January
2012 and January 2014 were included in this study. A diagnosis of
pulmonary embolsim was based on: chest pain, electrocardio-
graphic changes 2 D ECHO, D dimer, and typical time related
pattern of ABG, ECG, CT Pulmonary angiography and response to
treatment.
Results: Breathlessness was the most common presentation in 30
patients (78.92%), while chest pain in 6 patients(15.2%) and hy-
potension in 2 patients(5.7%). Incidence ofpulmonary embolism is
exceedingly higher inmales (78.92%) compared to females.Typical
symptoms seen in 70%.Risk factors such as prolonged bed rest,
immobilisation levels are more common in elderly patient-
s,whereas family history (22.10%) and diabetes(11.59%) are less
frequent.Prevalence of chest pain is almost same in younger
(76.81%) and elderly(78.6%) age group,most common sign being
tachypnea .74.25% of young patients with pulmonary embolism
received treatment in form of thrombolysis, most of the patiens
(85%) received streotokinase ,15% patients received tenectaplace.
4 patients received intrapulmonary thrombolysis with guidance
of catheter in PA.
Total 5 patients died, most of due to refractory hypotension .2
patients developed chronic pulmonary thromboembolism.
Elevated serum homocysteine levels are seen in 28(10.14%) of
young patients.Primary thrombolysis had good outcome in < 40
years age group.Postprocedure complications are almost negli-
gible ( < 3%) in young age group.The incidence of in-hospital
congestive heart failure, and major bleeding were lowest(<2%) in
the youngest age group.
Conclusion: Younger patients have better outcome as compared
to elderly patients.
Tenectaplase in postoperative acute pulmonary
thromboembolism
S. Thrudeep, S. Gagan, G. Geofi, G. Rupesh, G. Rajesh,
T.G. Jayakumar, S. Abdul Khadar
Department of Cardiology, Amala Institute of Medical Sciences,
Thrissur, India
Background: The Incidence of Acute pulmonary thromboembo-
lism, as one of the post operative fatal complications, is around
1.6%. Management of embolism in postoperative cases is always
difficult and thus leading onto high rates of mortality and poor
prognosis. According to ESC guidelines, the use of Tenectaplase is
an important determining factor in the prognosis and
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